CD45RA T Cells: Immune Marker for Naive and Memory T Cell Regulation
What is CD45RA?
CD45RA is an isoform of the CD45 glycoprotein, a critical T cell marker widely expressed on naive T lymphocytes. These CD45RA+ T cells are essential for initiating fresh immune responses. In immunophenotyping and flow cytometry, the presence of CD45RA helps classify immune cells into naive, memory, and regulatory subsets, making it vital for both research and therapy.
CD45RA+ T Cells: Classification and Function
- Naive T Cells: CD45RA+ cells are primarily naive T cells that respond to new antigens and drive primary immune defense.
- Stem Cell-like Memory T Cells: A subset of CD45RA+ cells (TSCM) combines stem cell-like renewal with long-term immune memory.
- Regulatory T Cells (Tregs): CD45RA expression marks naive regulatory T cells (CD45RA+ FOXP3 low), known for strong immunosuppressive activity.
Difference Between CD45RA+ and CD45RO+
| CD45RA+ | CD45RO+ |
|---|---|
| Naive T Cells | Memory T Cells |
| Unexposed to antigens | Previously activated |
| High proliferative potential | Rapid response upon re-exposure |
Therapeutic Applications of CD45RA+ Cells
- Immune Reset: CD45RA+ cells are used in immune reset therapies for autoimmune diseases like Multiple Sclerosis and Type 1 Diabetes.
- Cancer Immunotherapy: Naive CD45RA+ T cells are being applied in CAR-T cell therapy for enhanced persistence and expansion.
- Regulatory Therapies: CD45RA+ Tregs help prevent graft-versus-host disease (GVHD) after transplants.
Genestac’s Role in CD45RA+ Enrichment
At Genestac Therapeutics, we specialize in sorting and enrichment of CD45RA+ T cells using FACS and MACS under GMP conditions. Our expertise supports:
- Naive T cell-based immunotherapy
- Regulatory T cell trials
- Autologous and allogeneic CAR-T development
Conclusion
CD45RA+ cells form the backbone of immune system renewal, from naive T cells to regulatory subsets. They hold promise in cancer immunotherapy, autoimmune control, and immune reconstitution. Research by NCBI highlights CD45RA’s role in advancing immunology. With Genestac’s precision enrichment, CD45RA+ cells are enabling safer, more effective clinical outcomes.
Frequently Asked Questions (FAQs)
Why is CD45RA important in immunotherapy?
CD45RA+ naive T cells provide strong persistence and adaptability, making them valuable in cancer and autoimmune therapies.
Can CD45RA+ cells be used in autoimmune diseases?
Yes. CD45RA+ regulatory T cells suppress abnormal immune activity in conditions like Crohn’s, lupus, and multiple sclerosis.
What is the difference between CD45RA and CD45RO?
CD45RA marks naive T cells with high proliferative capacity, while CD45RO marks memory T cells that respond quickly to previously encountered antigens.
How does Genestac use CD45RA+ enrichment?
Genestac Therapeutics enriches CD45RA+ T cells using FACS and MACS technology under GMP conditions, supporting CAR-T, Treg, and immune reset therapies.